Before genetic testing: what the answer could change

Begin with the reason for testing

The same laboratory test can carry a different meaning depending on who is being tested and why.

Diagnostic testing is performed in someone who has symptoms. The goal may be to identify the cause of a neurologic condition, distinguish between overlapping diagnoses, or guide care and research options.

Predictive or presymptomatic testing is performed in someone who does not have symptoms but may have inherited a familial pathogenic variant. This is most informative when the family's specific variant has already been identified in an affected relative.

Risk testing looks for variants that change probability rather than determine an outcome. APOE testing for future Alzheimer's risk is an example. A risk result cannot tell one person whether or when disease will develop.

Treatment-related testing may help assess whether a medicine has a particular risk. APOE testing is now used in discussions of amyloid-lowering treatment because APOE status is associated with the risk of amyloid-related imaging abnormalities, or ARIA.

Test the most informative person when possible

If several relatives have had a similar condition, testing a relative who has symptoms is often the clearest place to begin. Finding a pathogenic variant in an affected person establishes a specific target that other adult relatives can choose to test for.

Starting with an unaffected relative can be less informative. A negative broad panel may mean the person did not inherit a detectable familial variant. It may also mean that the family's cause was not included, cannot be detected by that method, or has not yet been discovered.

Sometimes the affected relative is no longer living or cannot be tested. Testing may still be reasonable, but the limits of a negative result should be discussed beforehand.

The name of the panel is not enough

Genetic tests use different methods. A targeted test looks for one known family variant. A multigene panel examines a selected group of genes. Exome or genome testing surveys a much larger part of the DNA.

Some important changes require a separate method. The expansion in C9orf72 and the repeat expansion in HTT are examples. Standard sequence analysis may not detect them. Some deletions or duplications also require dedicated analysis.

Before testing, ask for the name of the laboratory, the genes included, the methods used, and the important categories of change the test does not detect.

Prepare for more than positive or negative

A test may return several types of answer.

Pathogenic or likely pathogenic means that the evidence supports a disease-causing role. The clinical meaning still depends on the gene, the condition, the person's symptoms, and the penetrance of that variant.

Negative means that the test did not find a reportable explanation within what it examined. It can be a true negative when a known familial variant was specifically tested and not found. A negative broad panel without a known family variant is often less conclusive.

Variant of uncertain significance, often shortened to VUS, means that a DNA difference was found but current evidence cannot determine whether it contributes to disease. A VUS should not be used by itself to diagnose a condition or test unaffected relatives for future disease risk.

Risk allele means that the result changes probability. It is not equivalent to a pathogenic variant in a highly penetrant disease gene.

What a result may mean for relatives

DNA is shared. A result in one person may reveal that a sibling, child, parent, or extended relative could also carry a variant. Family members may differ in whether they want that information and when they want it.

Testing can affect emotions, relationships, family planning, and decisions about the future. A person may feel relief, grief, anxiety, guilt, clarity, or no strong reaction at all. Genetic counseling is not intended to persuade someone to test. It is a way to make the choice informed and to plan how results will be received and shared.

Predictive testing for an adult-onset neurologic disease is generally approached differently from diagnostic testing in a person who already has symptoms. Testing children for an adult-onset condition is usually avoided when the result would not change care during childhood.

Privacy and insurance deserve a specific conversation

In the United States, the Genetic Information Nondiscrimination Act, or GINA, provides protections involving most health insurance and employment decisions. It does not provide the same federal protection for life, disability, or long-term care insurance. State laws vary.

Direct-to-consumer testing also raises questions about data storage, secondary use, research, and third-party interpretation. A consumer or research result may need confirmation in a clinical laboratory before it is used for medical care.

This is an area where current legal, insurance, and laboratory guidance matters. A genetic counselor can help identify the questions that apply to the person's location and circumstances.

Decide what happens after the result

Before the sample is sent, there should be a plan for who will disclose the result, what follow-up is available, and which medical decisions could change. The plan should also account for an uncertain or uninformative result.

The useful question is not simply, "Can this test be ordered?" It is, "What will we do with each possible answer?"